231. Alpha-1-antitrypsin deficiency Clinical trials / Disease details
Clinical trials : 89 / Drugs : 89 - (DrugBank : 16) / Drug target genes : 35 - Drug target pathways : 47
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03008915 (ClinicalTrials.gov) | January 2017 | 22/12/2016 | Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency | Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency | Alpha-1 Antitrypsin Deficiency;Emphysema;Chronic Obstructive Pulmonary Disease | Drug: Aspirin;Drug: Placebo;Other: Withdrawal from alpha1 antitrypsin replacement therapy | Columbia University | Alpha-1 Foundation;Stony Wold-Herbert Fund, Inc. | Active, not recruiting | 40 Years | N/A | All | 15 | Phase 2 | United States |